NEW YORK, Jan. 6, 2022 /PRNewswire/ — Hemophilia Therapeutics Market Facts at a Glance-
- Total Pages: 120
- Companies: 10+ – Including Baxter International Inc., Bayer AG, Biogen Inc., CHIESI Farmaceutici SpA, CSL Ltd., F. Hoffmann-La Roche Ltd., Novo Nordisk AS, Pfizer Inc., Sanofi SA, and Takeda Pharmaceutical Co. Ltd.
- Coverage: Key drivers, trends, and challenges; Product insights & news; Value chain analysis; Parent market analysis; Vendor landscape; COVID impact & recovery analysis
- Segments: Type (hemophilia A, hemophilia B, and hemophilia C)
- Geographies: North America, Europe, Asia, and ROW
Didn’t Find What You Were Looking For? Customize Report-
Don’t miss out on the opportunity to speak to our analyst and know more insights about this market report. Our analysts can help you customize this report according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short time.
We offer USD 1,000 worth of FREE customization at the time of purchase. Speak to our Analyst now!
According to the recent market study by Technavio, the Hemophilia Therapeutics Market Size is expected to increase by USD 4.47 billion from 2020 to 2025, progressing at a CAGR of 6.16% during the forecast period. The report provides a detailed analysis of drivers & opportunities, top winning strategies, competitive scenario, future market trends, market size & estimations, and major investment pockets.
North America will register the highest growth rate, occupying 41% of the global market share. The US and Canada are the key markets for hemophilia therapeutics in North America. However, the market growth in this region will be slower than the growth of the market in Asia.
Download FREE Sample: for more additional information about the key countries in North America
Vendor Insights-
The hemophilia therapeutics market is fragmented is highly consolidated. The rising competition in the market is driving vendors to increase their R&D efforts and introduce efficient novel drugs. The market is also witnessing the entry of new players offering innovative products. This is driving some vendors to form strategic alliances to expand their product portfolios and enter new markets.
Baxter International Inc.: The company offers BAX 855 hemophilia therapeutics for the treatment of hemophilia A.
Bayer AG: The company offers hemophilia care unit for the treatment of hemophilia A.
Biogen Inc.: The company offers Eloctate hemophilia therapeutics for the treatment of hemophilic A.
CHIESI Farmaceutici SpA: The company offers hemophilia care unit for the treatment of hemophilia A.
CSL Ltd.: The company offers Afstyla, humate-P, Helixate FS hemophilia therapeutics for the treatment of hemophilia A.
Find additional highlights on the vendors and their product offerings. Download Free Sample Report
Regional Market Outlook
The hemophilia therapeutics market growth in North America will be significant during the forecast period. The increasing prevalence of hemophilia is driving the growth of the hemophilia market in North America. In addition, factors such as reduced cost of pharmaceutical therapeutics, increased access to healthcare, and improved quality of healthcare are fostering the regional market growth.
Download our FREE sample report for more key highlights on the regional market share of most of the above-mentioned countries.
Latest Drivers & Trends Driving the Market-
- Hemophilia Therapeutics Market Driver:
- New drug approvals:
Patients with hemophilia were treated with replacement therapy in the past years. It involved the replacement of whole blood and fresh frozen plasma. However, with the approval of new therapeutics, patients are given the option of choosing different effective and safe treatments. Also, the development and approval of new therapeutics with high efficacy will drive the growth of the market during the forecast period.
- Hemophilia therapeutics Market Challenge:
- Increased use of technologies for the development of innovative products:
Many hemophilia drugs available in the market exhibit immunogenic reactions, which reduces their efficacy. To overcome such issues, vendors in the market are leveraging technologies such as recombinant DNA, protein fusion, and PEGylation technologies to develop new therapies. This trend is expected to have a positive impact on the growth of the market.
Find additional information about various other market Drivers & Trends mentioned in our FREE sample report.
Related Reports:
Von Willebrand Disease Therapeutics Market by Product and Geography Forecast and Analysis 2021-2025
| Hemophilia Therapeutics Market Scope | |
| Report Coverage | Details |
| Page number | 120 |
| Base year | 2020 |
| Forecast period | 2021-2025 |
| Growth momentum & CAGR | Accelerate at a CAGR of 6.16% |
| Market growth 2021-2025 | USD 4.47 billion |
| Market structure | Fragmented |
| YoY growth (%) | 5.85 |
| Regional analysis | North America, Europe, Asia, and ROW |
| Performing market contribution | North America at 41% |
| Key consumer countries | US, UK, Germany, China, and Canada |
| Competitive landscape | Leading companies, competitive strategies, consumer engagement scope |
| Companies profiled | Baxter International Inc., Bayer AG, Biogen Inc., CHIESI Farmaceutici SpA, CSL Ltd., F. Hoffmann-La Roche Ltd., Novo Nordisk AS, Pfizer Inc., Sanofi SA, and Takeda Pharmaceutical Co. Ltd. |
| Market Dynamics | Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, market condition analysis for the forecast period. |
| Customization purview | If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
View original content to download multimedia:https://www.prnewswire.com/news-releases/hemophilia-therapeutics-market-to-record-usd-4-47-bn-growth–baxter-international-inc-bayer-ag-biogen-inc-and-chiesi-farmaceutici-spa-emerge-as-dominant-players–technavio-301455353.html
SOURCE Technavio
